The complications of metastatic bone disease (MBD) in advanced cancer, especially skeletal-related events (SREs), are a significant cause of morbidity that can seriously impair the quality of patients' lives. Treatments that prevent SREs, reduce or delay the onset of pain and preserve function and activities of daily living are central to good patient care. In this article, we discuss results from clinical trials that show the relative benefits and harms of different bone-targeted agents, which may be given orally, intravenously or subcutaneously.
(ibandronate, pamidronate, zoledronic acid) are considered more potent than earlier generation drugs such as clodronate and have different side-effect profiles. While approvals by cancer type are country-and region-specific, ibandronate, clodronate and pamidronate have demonstrated efficacy in patients with metastatic breast cancer and bone lesions from multiple myeloma. Zoledronic acid is approved to prevent SREs (including tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone.
The newest bone-targeted therapy, denosumab, is a fully human monoclonal antibody with high affinity and specificity for the signalling protein RANK ligand (RANKL). Denosumab prevents the interaction of RANKL with its RANK-binding site on the surface of osteoclasts. This reduces osteoclast formation, function and survival, inhibiting osteoclast-mediated bone destruction dramatically. 12, 13 Unlike bisphosphonates, denosumab is administered by subcutaneous injection and has proven more effective than zoledronic acid in preventing SREs in patients with bone metastases from solid tumours. [14] [15] [16] Denosumab is not indicated in Europe for the prevention of SREs in patients with multiple myeloma.
In this paper, we review the currently available treatments and their efficacy in relation to reducing skeletal complications from MBD. We also consider comparative treatment characteristics that may help to maintain, rather than impede, a good quality of life, and summarise the relative advantages and disadvantages of different treatments based on patient-centred attributes. In order to provide focused and in-depth discussion, this article addresses only MBD from solid tumours, not from multiple myeloma.
Considering Efficacy and More
As more cancer treatments now prolong both progression-free and overall survival, there is an increasing need to ensure that patients'
health-related quality of life (HRQoL) is optimally maintained as well.
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When choosing between treatment possibilities for advanced cancer, patient preferences should be taken into account. Clinicians and patients can together evaluate the advantages and disadvantages of the different options based on factors beyond treatment efficacy.
Clinicians tend to focus more on disease-related factors (such as previous therapies and response, tumour burden and the need for rapid disease or symptom control 18 ), whereas patients tend to place greater emphasis on HRQoL (including burden of treatment, treatment side effects and impact on their lifestyle and family) and on the tangible and intangible costs of treatment. 19 These more psychosocial issues are often difficult to quantify, but their consideration can provide valuable guidance when clinicians discuss the various treatment options available with individual patients. HRQoL-related factors can not only aid optimal decision-making, but can also improve physician-patient communication, which may lead to better outcomes for some cancer patients.
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The issues beyond efficacy that merit discussion include details about the mode and frequency of administration, availability of therapy, the relative acceptability of side effects and, in some healthcare systems, funding for the agent. Other factors important to patients include their own out-of-pocket costs -incurred through travel and time for extra testing or monitoring -and the added financial burden that might be sustained by care-givers. Treatment Options for Metastatic Bone Disease in Solid Tumours More work in this area, taking preferences of real patients into account, is warranted, as research on the subject was done before the development of subcutaneous routes of administration and hence considers only oral and intravenous experiences.
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Cost of Treatment
The cost of bone-targeted treatment affects patients as it can determine whether a therapy is available for clinicians to prescribe. 
Efficacy
The efficacy of bisphosphonates in delaying cancer-related skeletal complications is influenced by the potency of the bisphosphonate, its bioavailability and patient adherence to treatment. The order from lowest to highest potency is as follows: clodronate, pamidronate, ibandronate and zoledronic acid. 35 Oral formulations are available for clodronate and ibandronate, but their bioavailability is much less than that of bisphosphonates administered intravenously, particularly if they are not taken according to the strict administration instructions. 36,37 All bisphosphonates have a long half-life because they accumulate within bone, where they are incorporated integrally into the bone structure. Despite this long half-life, metabolic activity is a function of the free levels of the drug; hence, the activity of this class of agents in MBD is shortened by the local resorptive drive of the tumour. Also, the risk of skeletal complications after zoledronic acid treatment is a function of persistence of use.
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Denosumab shows a bioavailability of >60 %. 39 It is not deposited in bone and its effects are reversible. 40 As with all monoclonal antibodies, denosumab is likely eliminated by the reticuloendothelial system, 41 with no effect on renal function, in contrast to bisphosphonates, which are excreted by the kidneys and are nephrotoxic. 42 Head-to-head comparative trials of denosumab and zoledronic acid showed that denosumab is significantly more effective at reducing the rate of SREs in patients with solid tumours and bone metastases. 43 Supportive Oncology
also reduced the risk of any on-study SRE by 19 % compared with zoledronic acid (relative risk 0.81, 95 % CI 0.74-0.88; p<0.0001). 44 The comparative effectiveness of denosumab and zoledronic acid has also been assessed using a number needed to treat (NNT)
analysis. This method describes effectiveness in terms of people who may be affected, rather than a percentage risk reduction.
A lower NNT represents a more beneficial treatment outcome. NNT analyses between denosumab and zoledronic acid demonstrated a greater treatment benefit with denosumab across tumour types:
treatment of seven patients with denosumab would prevent an additional SRE per year in patients with breast cancer metastatic to bone 45 and in patients with other advanced solid tumours, 46 while treatment of five patients with denosumab would prevent an additional SRE per year in patients with castration-resistant prostate cancer metastatic to bone. 47 
Patient-reported Outcomes
The impact that different bone-targeted therapies in MBD patients with advanced cancer have on pain is important. Fear and other psychosocial dimensions of pain should not be overlooked. 48, 49 Results from a plethora of studies investigating the effects of bisphosphonates on bone pain across cancer sites have been summarised in systematic reviews. [50] [51] [52] The balance of evidence indicates that oral clodronate has little effect on bone pain in metastatic breast cancer, whereas both oral and intravenous ibandronate have produced significant reductions compared with placebo. 50 Intravenous pamidronate improved pain scores compared with placebo 53 and also improved pain scores compared with oral clodronate over three months of treatment in a small comparative trial in breast cancer. 54 Zoledronic acid, compared with placebo, has been found to attenuate pain worsening in metastatic prostate cancer 55, 56 and reduce pain in patients with breast cancer. 57 In the head-to-head trials of denosumab and zoledronic acid in breast cancer, prostate cancer and other solid tumours, denosumab was more effective at delaying the onset of significant pain, particularly in patients with no or mild pain at initiation of treatment. In these patients, denosumab reduced the risk of pain worsening to moderate or severe compared with zoledronic acid by 22 % in breast cancer (p=0.0024), 11 % in prostate cancer (p=0.14) and 19 % in other solid tumours (p=0.050), with median delays in pain worsening of one to four months depending on tumour type. [58] [59] [60] Denosumab and zoledronic acid were similarly effective in palliating pain.
Some bone-targeted therapies have been found to influence analgesic use for pain relief. A German clinic-based study of breast cancer patients found that, with ibandronate therapy, more patients ceased taking analgesics and fewer patients required more potent analgesia by the end of the study than at enrollment. 61 Analyses of data pooled from oral and intravenous clodronate trials in solid tumours found an increased proportion of patients requiring less analgesia at four and 12 weeks compared with patients receiving placebo. 52 The comparative denosumab and zoledronic acid trials across advanced cancers collectively showed that fewer denosumab-treated patients reported shifts from no or low analgesic use at baseline to strong opioid-level analgesic use by study end. 62 The direct effects of bone-targeted agents on general measures of patients' HRQoL can be challenging to quantify, but some The potential for increased nephrotoxicity is of concern with both oral and intravenous bisphosphonates, as these agents are eliminated via the kidneys and, when used in higher doses or infused rapidly, can induce renal impairment in patients with previously normal renal function. 55 The type of bisphosphonate and differences in half-life, intravenous bisphosphonate dosing and/or infusion rate may require adjustments based on CRcl. 42, 72 Bisphosphonates have to be withheld until serum creatinine levels recover sufficiently. 73 Bisphosphonates are not recommended for patients with severe renal impairment (CRcl <30 ml/minute), 73 with the exception of ibandronate, which, per the label, can be administered at a reduced dose in patients with CRcl <30 ml/minute. 74 Denosumab, which is not associated with renal toxicity, does not require renal monitoring or dose adjustment, nor does it have to be withheld from patients with renal dysfunction. 75 As expected for agents that inhibit bone resorption and the associated calcium release from bone, decreases in serum calcium levels can occur with both denosumab and zoledronic acid. In the comparative trials of denosumab and zoledronic acid, the incidence of hypocalcaemia was generally low, but more frequent with denosumab than with zoledronic acid across solid tumours (9.5 % versus 4.8 %, respectively, in integrated analyses in patients with solid tumours only). 44 In the post-marketing setting, cases of severe hypocalcaemia (including rare symptomatic cases) have been reported in patients receiving zoledronic acid 76 or denosumab, 75 and rare fatal cases of severe hypocalcaemia have been reported in patients receiving denosumab who had advanced metastatic cancer and other concurrent medical conditions; 75 the patients receiving denosumab were also taking a variety of other concurrent medications, including anticancer therapies; it is not known if the concurrent conditions and therapies contributed to the hypocalcaemia or the fatal outcomes in these patients.
Treatment Options for Metastatic Bone Disease in Solid Tumours
Pre-existing hypocalcaemia must be corrected prior to initiating bone-targeted therapy, and it is important that clinicians advise their patients to take calcium and vitamin D supplements during treatment.
Patients with significant renal dysfunction (CRcl <30 ml/min) or who are on active dialysis are at increased risk of hypocalcaemia. Thus, when initiating bone-targeted therapy in these patients, it may be prudent to plan more frequent monitoring of calcium levels.
Osteonecrosis of the jaw (ONJ) occurs with very low frequency but can be a serious adverse event with both denosumab and intravenous bisphosphonates. Among 5,723 patients in the denosumab versus zoledronic acid comparative trials, where ONJ was independently adjudicated, ONJ occurred in 1.6 % of patients overall (1.8 % receiving denosumab and 1.3 % receiving zoledronic acid; p=0.13); over half of these cases were treated conservatively. 77 Symptoms of this adverse event can include swelling and numbness, pain, infection or drainage in the jaw. Conservative management of ONJ is generally recommended using antibiotics, oral rinses and limited debridement.
Aggressive treatment by surgery and bone resection is only required in patients with severe manifestations of the condition. 78, 79 The most common risk factors leading to ONJ in patients receiving bisphosphonates or denosumab are pre-existing dental or gum disease and invasive dental procedures such as tooth extraction. 80 Preventive dentistry is recommended prior to initiation of bone-targeted agents in patients with poor oral hygiene or dentition.
Clinicians should proactively encourage good dental hygiene practices in their patients to manage ONJ severity or to reduce the risk of ONJ, as it can be preventable. 81 Although some tumour types, patient features and other considerations will dictate the bone-targeted treatments to be offered (for example, pamidronate is ineffective in prostate cancer 82 ), clinicians nevertheless still have large numbers of patients for whom there is a variety of available treatment options.
Discussion
Although the efficacy of bone-targeted therapies is a key factor in the Supportive Oncology 
